
There are probably several reasons for this practice, such as scepticism about the result in ESRD patients given the proven efficacy of statins in other groups, or a reluctance to engage in therapeutic nihilism. Personally, I worry about precipitating a cardiovascular event by stopping these drugs; the 4D and Aurora trials do not address the issue of discontinuation. With such a high rate of cardiovascular events in this population, aren't you just asking for trouble by drawing a line through the Lipitor on the medsheet? It's a thorny question, and one we may put to poll on this blog next week.
2 comments:
Nice post. This is definitely a tough issue. Although I no longer feel compelled to start statins on dialysis pts, I do not feel strong enough to advocate enthusiastically for discontinuation.
You can't have it both ways.
Post a Comment